The therapeutic potential of anti-cytokine antibodies in the treatment of chronic inflammatory disease
| Autor: | Natalie J Davidson |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Pharmacology
biology medicine.drug_class business.industry medicine.medical_treatment Inflammation General Medicine Disease medicine.disease Monoclonal antibody Inflammatory bowel disease Cytokine Rheumatoid arthritis Immunology medicine biology.protein Pharmacology (medical) Animal studies medicine.symptom Antibody business |
| Zdroj: | Expert Opinion on Investigational Drugs. 7:1115-1120 |
| ISSN: | 1744-7658 1354-3784 |
| DOI: | 10.1517/13543784.7.7.1115 |
| Popis: | The outcome of inflammatory diseases is likely to be dependent upon the relative balance of pro- versus anti-inflammatory cytokines. Control of this balance through the use of anti-cytokine monoclonal antibodies (mAbs) promises to be an effective means of disease therapy. The treatment of rheumatoid arthritis (RA) or inflammatory bowel disease (IBD) with anti- tumour necrosis factor alpha (TNF-alpha) mAb has dramatically ameliorated disease symptoms, indicating that such a treatment approach can be highly successful. Similarly, based on animal studies, the use of neutralising anti-interleukin (IL)-12 mAb may prove efficacious in a number of inflammatory disorders, particularly for IBD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|